Kornimate/medical-research-clean huggingface dataset:
prp vs corticosteroid in baker's cyst

Conditions: Baker's Cyst

Summary: this is a prospective study with randomized patients into either ultrasound-guided platelets-rich-plasma injection and ultrasound guided corticosteroid injection, with 3 months and 6 months follow ups after aspiration at our institution. there will be 25 patients in each group, including any patient with symptomatic baker's cyst.

the treatment of baker's cysts are based on its presentation, asymptomatic cysts are currently managed conservatively, symptomatic cysts are treated with joint aspiration and corticosteroid injection, which have shown according to literature a decrease of the cyst size in approximately two-thirds of patients within 2-7 days but only complete disappearance in approximately 7 %. ultrasound guided cyst aspiration and corticosteroid injection are also used with reduction of cyst's size with recurrence in 6 months of 19%. surgical options to remove the cyst include, open resection with a recurrence of 50%, 25% of patients have motion limitation recurrence, 37% have wound healing problems or tense swelling of the calf and 75% of patients have joint pain lasting more than 2 days. arthroscopic resection, with no recurrence in ultrasound performed 6 and 12 months after procedure, pain lasting more than 3 days in 28% of patients, mild hematoma in 7% of patients and 7% where converted into an open procedure there is no study using ultrasound guided aspiration with platelet-rich-plasma injection (prp). the rationale for the use of prp is the belief that the additional platelets will exponentially increase the concentration and release of multiple growth and differentiation factors at the injury site to augment the natural healing process9. prp does not have any described negative side effect due to the fact that is being prepared from subject's own blood, with no risk of allergy or cross infection, relatively easy for a practiced clinician, and reproducible.

Eligibility criteria:
inclusion criteria: * patients at least 18 years old. * patients with baker's cyst who also present with at least one of the following: swelling, local pain or discomfort, limited range of motion or any other symptom directly caused by the baker's cyst. exclusion criteria: * patients younger than 18 years old * local or systemic active infection * active cancer treatment * immunodeficiency * diabetes * hypersensitivity or allergy to corticosteroid or lidocaine

Keywords: baker's cyst
a study using 18f-faza and pet scans to study hypoxia in pancreatic cancer

Conditions: Pancreatic Cancer; Hypoxia

Summary: this is a diagnostic study to look for low levels of oxygen (hypoxia) in pancreatic cancer using an imaging test called positron emission tomography (pet). hypoxia can influence how pancreatic cancer grows and responds to treatments such as chemotherapy and radiotherapy. the use of pet scans to measure hypoxia may be better and simpler than the approaches used previously. this study will assess whether or not pet scans using a tracer called 18f-faza (18f-fluoroazomycin arabinoside) can provide useful information about hypoxia in pancreatic cancer. also as part of the study, a blood sample will be taken to study biomarkers (substances in the body that may be important indicators of hypoxia and/or pancreatic cancer) that may be useful in studying pancreatic cancer and hypoxia.

this is a single centre, single arm hypoxia study of pancreatic cancer with pet faza imaging. pet-ct imaging of tumor hypoxia with faza will be done prior to the start of standard treatment for pancreatic cancer with chemotherapy. the faza pet-ct imaging session will last approximately 2.5 hours and include an initial dynamic scan to completely characterize the initial rapid phase of faza uptake, followed by a later static scan.

Eligibility criteria:
inclusion criteria: * minimum age of 18 years old * histologic diagnosis of pancreatic adenocarcinoma * tnm (7th edition) ct1-4, n0-1, m0-1 * no cytotoxic anti-cancer therapy for advanced / metastatic pancreatic cancer prior to study entry * ability to provide written informed consent to participate in the study * ecog performance status 0, 1 or 2. * patient should have the following blood counts at baseline: anc equal or greater to 1.5 x 109/l; platelets equal or greater to 100 x 109/l; hgb equal or greater to 9g/dl * patient should have the following blood chemistry levels at baseline: ast (sgot), alt (sgpt) equal or less than 5 x upper limit of normal range (uln) is allowed * patient has an identifiable tumor (pancreatic tumor and/or metastasis) by imaging (ct scan and/or mr) * patient must agree to use contraception considered adequate and appropriate by the investigator and if the patient is female of child-bearing potential, as evidenced by regular menstrual periods, she must have a negative serum pregnancy test (b-hcg) exclusion criteria: * inability to lie supine for more than 30 minutes * any other type of primary cancer * life expectancy of less than 12 weeks * patient has known brain metastases unless previously treated and well controlled for at least 3 months (defined as stable clinically, no edema, no steroids and stable in two scans at least 4 weeks apart) * patient has serious medical risk factors involving any of the major organ systems

Keywords: hypoxia pancreas cancer pancreatic cancer 18f-faza 18f-fluoroazomycin arabinoside positron emission tomography pet
humoral immunity study after a booster dose of soberana plus (finlay-fr-1a) vaccine against covid-19

Conditions: Humoral Immunity

Summary: to evaluate the dynamics of igg levels to the sars-cov-2 virus after a booster dose of soberana plus vaccine.

prospective clinical study of evaluation of the immune response to booster dose of vaccine against covid-19 using enzyme immunoassay using the sunrise tecan microplate photometer (austria). the material is participants' plasma, obtained by the standard method. blood sampling performed 4 times: immediately before the first dose of vaccine, on day 42, 90 days and 180 days after booster dose of vaccine. booster dose of vaccine against coronavirus infection performing using approved and licensed vaccine soberana plus (republic of cuba). venous blood sampling performing standardly. all study participants are informed about the study objectives and upcoming procedures, and all of them given informed written consent to participate the study. a reagent kit manufactured by vector-best (russian federation) and designed for enzyme immunoassay for quantitative detection of sars-cov-2 class g immunoglobulins, sars-cov-2-igg quantitative elisa-best, d-5505 sars-cov-2-igg (series 5, 6) ру № рзн 2022/17065т used for immunoassay. the "sars-cov-2-igg quantitative elisa-best" reagent kit design uses recombinant full-length trimerized s glycoprotein (spike) of the sars-cov-2 virus derived from a eukaryotic expression system. the protein molecule+ consists of two subunits, s1 containing the rbd domain and s2. the reagent kit "sars-cov-2-igg quantitative elisa-best" detects the pool of immunoglobulin class g synthesized to all antigenic determinants of protein s including the rbd-domain. the quantification of the sars-cov-2 antibody assay is based on the who first international standard (nibsc code:20/136) and expressed in international units (bau/ml). analytical characteristics of reagent kit "sars-cov-2-igg quantitative elisa-best (series 5, 6)" were: linearity - within 90-110%, considering the analytical results at wavelengths 405 nm and 415 nm - within the concentration range igg к sars-cov-2 10-5000 bau/ml; reproducibility: the coefficient of variation does not exceed 8%). the "opening" test - within 90-110% (samples with absorbances lower than 90% of the cut-off value are considered negative and samples with absorbances higher than 110% of the cut-off value are considered positive. the samples with absorbance in the range of 90-110% of cut-off value are equivocal). analytical sensitivity - minimal detectable concentration of igg to sars-cov-2 does not exceed 1.0 bau/ml.

Eligibility criteria:
inclusion criteria: 1. age 18-80 y.o.; 2. more that 4 months after the previous vaccination against covid-19; 3. no covid-19 infection registered within 30 days prior to soberana plus administration. exclusion criteria: 1. age less than 18 y.o. or more than 80 y.o.; 2. less than 4 months after the previous vaccination against covid-19; 3. covid-19 infection registered within 30 days prior to soberana plus administration.

Keywords: covid-19 sars-cov-2 humoral immunity booster dose
change in patient reported outcomes and wish for joint surgery

Conditions: Osteoarthritis, Knee and Hip

Summary: aim to investigate associations between within-person change in patient reported outcomes (proms) and wish for joint surgery during up to 12-month participation in a digital first-line intervention for knee and hip osteoarthritis (oa) comprising exercise and education. methods retrospective observational registry data. all participants enrolling between june 1st 2018 and september 30th 2021 with follow-up data and with a change in their wish for surgery (dichotomous, becoming wishing or unwishing) were included. analysed proms comprised pain (numeric rating scale (nrs), 0-10), 5 level euroqol - 5-dimension (eq5d-5l, 0.243-0.976), overall health (nrs, 0-10), activity impairment (nrs, 0-10), walking difficulties (yes/no), fear of movement (yes/no), function and quality of life subscales of knee/hip injury and osteoarthritis outcome score 12 items (koos-12/hoos-12, both 0-100). to capture effects of changes in proms over time on probability of wish for surgery, the investigators used fixed effect (conditional) logistic regressions.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of knee or hip osteoarthritis * date of enrolment between june 1st 2018 and september 30th 2021 (study period) * consent to the use of the data at the moment of enrolment (not withdrawn during the study period) exclusion criteria: * no follow-up data * no change in wish for surgery (participants remained either wishing or not wishing to undergo surgery for the whole treatment period). this exclusion was due to the focus of the present study on within-person relationships between proms and wish for surgery. in this scenario, those with no change in their wish for surgery do not provide any information to the analysis.

Keywords: osteoarthritis exercise wish for surgery digital intervention proms
monitoring and characterization of coronary flow by transthoracic parametric doppler (tpd) during exercise stress test

Conditions: Coronary Artery Disease

Summary: the study is an open prospective study of coronary flow preferably of the left anterior descending artery (lad), by a transthoracic parametric doppler (tpd) system during conventional exercise stress test. the system is a noninvasive non-imaging device designed to monitor coronary flow velocity and display the data continuously during exercise stress tests. the system enables continuous monitoring of coronary flow during resting, stress loading and recovery phases. the study intent is to improve the stress test predictive value for cad.


Eligibility criteria:
inclusion criteria: * age 18 years or older * planned for ergometry test * signed informed consent exclusion criteria: * excluded for stress test on a treadmill
in utero alcoholic exposure: plgf, biomarker of fetal brain lesions

Conditions: Fetal Alcohol Syndrome

Summary: this study aims to validate that plgf is a biomarker of cerebral lesions and therefore of secondary developmental disorders and disabilities that will be best diagnosed at 2 and 6 years of age.


Eligibility criteria:
inclusion criteria: mother: * pregnant woman (monofetal or twin pregnancy, whatever the parity) * age\> or = to 18 years * person affiliated to a social security system * person who read and understood the information form and signed the consent form * alcohol exposure group chronic consumption of at least 30 g of alcohol per week or acute consumption of "binge drinking" type during pregnancy (knowing that a unit of 10 g of pure alcohol corresponds to 25 cl of beer 4 ° 5, 10 cl of wine at 12 °, 3 cl of whiskey, 7 cl of porto ...) * control group no alcohol consumption during pregnancy * child informed parents and written consent signed by the father and mother for the child's participation in this research (unless one of the parents does not have parental authority) exclusion criteria: * female under 18 * pregnant woman with clinical suspicion of pre-eclampsia and / or hellp syndrome * person deprived of liberty by an administrative or judicial decision or protected major subject (under tutorship or curatorship) * patient participating in another interventional trial or who participated in another interventional trial during pregnancy

Keywords: fetal alcohol syndrome pregnancy biomarker plgf cognitive development behavior troubles
testing strategies for increasing exercise

Conditions: Sedentary Lifestyle; Obesity

Summary: the purpose of the study is to learn more about effective ways to motivate people to increase their non-exercise energy expenditure exercise. this is an important research question because obesity and weight-related issues are increasingly becoming a problem in america. this project will address this research question by testing the effect of group dynamics in motivating employees who are predominantly sedentary to use walkstations at work. the walkstations are treadmills that move at a very slow rate (maximum 2miles / hour) and are attached to a work station (i.e. with computer and telephone); they therefore are designed to increase energy spent not through heavy exercise, but through small changes in posture and movement associated with routines in daily life (called nonexercise activity thermogenesis or neat). the proposed study is designed to build upon previous research (levine et al., 2005) suggesting the role of neat-enhanced behaviors in weight loss. in this study, the investigators are interested in the impact of group dynamics on the propensity to use the walkstations. participants in the active arms will be asked to use the walkstations for at least 3 hours per week. they will do so by signing up for a time slot. during their session, they will be asked to log into the scheduling system to indicate that they are using the walkstation. walkstation usage will be assessed by log-in data: employees will log-in to the phone and computer when they use the walkstation. this log-in data is work-station specific; therefore the investigators will be able to tell when a given subject used the walkstation. subjects will be randomly assigned to one of three conditions: 1. individual. in the individual condition, participants will not be part of a team. they will receive weekly email feedback on their walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.) participants will also receive a wellness tip in each email. (see appendix for a sample email) 2. pairs. in the pair condition, participants will be randomly assigned to a partner. they will receive the same feedback as those in the individual condition, for both themselves and their partner. 3. group. in the group condition, participants will be randomly assigned to a group of 5 people. they will receive the same feedback as those in the individual condition, for both themselves and each member of their group.


Eligibility criteria:
inclusion criteria: * must pass the parq * must be employee of bcbs massachusetts exclusion criteria: * failing the parq * not being an employee of bcbs massachusetts
effect of practical demonstration to use nasal spray and apply intranasal ointment on epistaxis

Conditions: Epistaxis

Summary: to compare the result of verbally educating the parents about method of intranasal antiseptic cream application versus practically educating and demonstrating how to apply cream intra nasally.

the primary outcome variables was control of epistaxis through history and clinical examination on follow up visits

Eligibility criteria:
inclusion criteria: * the children of age less than 12 years presenting with anterior recurrent epistaxis exclusion criteria: * o children with bleeding disorders. * children with liver and renal failure/dysfunction. * children using anti-coagulants. * those children who have gross deviated nasal septum or nasal polys etc. * cases who had history of nasal injuries secondary to trauma.

Keywords: epistaxis randomized control trial health education
a proof of concept study to evaluate the effects of tasimelteon and placebo in travelers with jet lag disorder

Conditions: Jet Lag Disorder

Summary: a proof of concept study to evaluate the effects of tasimelteon and placebo in travelers with jet lag disorder


Eligibility criteria:
inclusion criteria: * ability and acceptance to provide written consent * men or women between 18-75 years * body mass index of ≥ 18 and ≤ 30 kg/m2 exclusion criteria: * history (within the 12 months prior to screening) of psychiatric disorders * major surgery, trauma, illness or immobile for 3 or more days within the past month * pregnancy or recent pregnancy (within 6 weeks) * a positive test for drugs of abuse at the screening visit * any other sound medical reason as determined by the clinical investigator
preventative/preemptive adoptive transfer of peptide stimulated cmv/ebv specific t-cells in patients after allogeneic stem cell transplantation

Conditions: Patients Undergoing Allogeneic Stem Cell Transplantation

Summary: in patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as cytomegalovirus (cmv) and epstein barr virus (ebv) is a frequent and life threatening complication requiring antiviral treatment. the underlying problem is a severe suppression of the donors immune system after transplantation into the patient. herpesviruses such as cmv and ebv persist after primary infection life long in the host and therefore require constant immunological control. this control is largely provided by the t-cell compartment of the immune system. after allogeneic stem cell transplantation the t-cell compartment requires a long time for its reconstitution since only a small fraction of the donor t-cells are transplanted. during this time herpesviruses can reoccur due to the lack of effective t-cell control. this study therefore aims at reconstituting the t-cell compartment with cmv and ebv specific t-cells at an early time point after allogeneic stem cell transplantation. it is mainly a phase i study to demonstrate that these in vitro generated t-cells can be applied safely in this patient population. the study also aims at demonstrating the efficacy of cmv/ebv specific t-cells by monitoring viral reactivation and use of antiviral drugs. the hypothesis is, that cmv/ebv specific t-cell can be applied safely and do not result in graft versus host disease and that they successfully prevent reactivation of cmv and ebv after adoptive transfer in patients after allogeneic stem cell transplantation.


Eligibility criteria:
inclusion criteria: * indication for allogeneic stem cell transplantation * hla identical donor, related or unrelated, 10/10 match * stem cell source: g-scf mobilized peripheral blood stem cells * presence of at least one hla allele: a0101, a0201, b0702, b0801, b3501, c0702 * positive ebv serology of the donor * positive cmv serology of the donor * adequate contraception exclusion criteria: * donor cmv seronegative * donor ebv seronegative * stem cell source: bone marrow or cord blood * alemtuzumab for conditioning * sorror score \>3 * pregnancy

Keywords: cmv cytomegalovirus ebv epstein barr virus virus t cell adoptive transfer transplantation allogeneic
becoming united in lifestyle decisions

Conditions: Overweight and Obesity

Summary: the goal of this project is to investigate how to enhance the effects of an online-only (mhealth) couples weight loss program. this study will use an innovative methodological framework, the multiphase optimization strategy (most), to test four different strategies for weight loss and partner support in addition to a core intervention (i.e., dyadic action planning, joint feedback on goal progress, autonomy support training, and home environment modifications).


Eligibility criteria:
inclusion criteria: * married/cohabitating couple - both partners must be eligible * bmi between 25-55kg/m2 * english speaking/reading * have a smartphone and reliable internet access * have active email address * willing to videoconference exclusion criteria: * report being unable to walk 2 blocks without stopping * are currently participating in weight loss treatment, have a history of bariatric surgery, or lost ≥5% in the past 6-months * are pregnant or plan to become pregnant during the study period * report chest pain or loss of consciousness on the physical activity readiness questionnaire * report a medical condition that could jeopardize their safety in a weight control program with diet and exercise guidelines * report conditions that, in the judgment of the pi, would render them unlikely to follow the protocol (e.g. dementia)

Keywords: couples mobile weight loss treatment weight control
revision total hip replacement arthroplasty and hematologic variables

Conditions: Avascular Necrosis of Hip; Degenerative Hip Joint Disease

Summary: revision total hip replacement arthroplasty is a surgery having intra- and postoperative substantial blood loss. the investigators will investigate the relationship between the various hematologic variables and postoperative bleeding volume.


Eligibility criteria:
inclusion criteria: * revision total hip replacement exclusion criteria: * hematologic disease * anticoagulant medication * american society of anesthesiologists physical status 4 and 5
studying of natural constituents' treatment of plantar warts

Conditions: Plantar Wart

Summary: moringa banana nigella and banna coat extract were prepared and formulated in the form of bi gel for transdermal delivery of these plant extracts. the formulation was prepared and charterized for organoleptic charters, morphology, and penetration efficacy. the optimised formulation was assessed clinically on patients suffering from plantar warts. the clinical study was phase 1 and interventional randomised allocation.


Eligibility criteria:
inclusion criteria: * male or female patient aged 18 years or more. * clinical evaluation * number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm exclusion criteria: * patient suspected to be immunocompromised * patient aged under 18 years * patient refusing to sign the consent * pregnant or lactating women